1-888-INFO-FDA (1-888-463-6332) Contact FDA. 1-888-INFO-FDA (1-888-463-6332) Contact FDA. Tasigna may be given in combination with hematopoietic growth factors such as erythropoietin or G-CSF if clinically avodart used for indicated. Tasigna may be given in combination with hematopoietic growth factors such as erythropoietin or G-CSF if clinically indicated. Dosage in Newly Diagnosed Ph+ CML-CP. Dosage in Newly Diagnosed Ph+ CML-CP. 10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. 10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. The recommended dose of Tasigna is 300 mg orally twice daily [see Clinical Pharmacology (12. The recommended dose fda tasigna of Tasigna is 300 mg orally twice daily [see Clinical Pharmacology (12. The recommended dose of Tasigna is 300 mg orally twice-daily [see Clinical Pharmacology (12. The recommended dose of Tasigna is 300 mg orally twice-daily [see Clinical Pharmacology (12. Tasigna may be given with hydroxyurea or anagrelide if clinically indicated. Tasigna may be given with hydroxyurea or anagrelide if clinically indicated. 5 (BCR-ABL1 International Scale [IS]. 5 (BCR-ABL1 International Scale [IS]. Tasigna may be given with hydroxyurea or anagrelide if clinically indicated. Tasigna may be given with hydroxyurea or anagrelide if clinically indicated. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) Tasigna may be given in combination with hematopoietic growth factors such as erythropoietin or G-CSF if clinically indicated. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) Tasigna may be given in combination with hematopoietic growth factors such as erythropoietin or G-CSF fda tasigna if clinically indicated.